The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Pharmacology of anabolic steroids
Open accessAbstract
Athletes and bodybuilders have recognized for several decades that the use of anabolic steroids can promote muscle growth and strength but it is only relatively recently that these agents are being revisited for clinical purposes. Anabolic steroids are being considered for the treatment of cachexia associated with chronic disease states, and to address loss of muscle mass in the elderly, but nevertheless their efficacy still needs to be demonstrated in terms of improved physical function and quality of life. In sport, these agents are performance enhancers, this being particularly apparent in women, although there is a high risk of virilization despite the favourable myotrophic–androgenic dissociation that many xenobiotic steroids confer. Modulation of androgen receptor expression appears to be key to partial dissociation, with consideration of both intracellular steroid metabolism and the topology of the bound androgen receptor interacting with co‐activators. An anticatabolic effect, by interfering with glucocorticoid receptor expression, remains an attractive hypothesis. Behavioural changes by non‐genomic and genomic pathways probably help motivate training. Anabolic steroids continue to be the most common adverse finding in sport and, although apparently rare, designer steroids have been synthesized in an attempt to circumvent the dope test. Doping with anabolic steroids can result in damage to health, as recorded meticulously in the former German Democratic Republic. Even so, it is important not to exaggerate the medical risks associated with their administration for sporting or bodybuilding purposes but to emphasize to users that an attitude of personal invulnerability to their adverse effects is certainly misguided. British Journal of Pharmacology(2008)154, 502–521; doi:fn1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Biological Actions of Androgens
MOORADIAN, A. D., MORLEY, J. E., & KORENMAN, S. G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-1-1 · Cited by 1,080
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 3×
“…doubling of the serum total and free concentrations of testosterone from the baseline values in eugonadal men over a 20-week period caused significant increases in strength and power (see the results reported by Bhasin et al. (2001), regarding the weekly regimen of 300 mg testosterone enanthate).”
BackgroundAndrogen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727
Handbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Pope, H. G. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050035004 · Cited by 604
The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions
Heinlein, C. A., & Chang, C. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0070 · Cited by 568
Cited by
British Thoracic Society guideline on pulmonary rehabilitation in adults: accredited by NICE
Bolton, C. E., Bevan-Smith, E. F., Blakey, J. D., Crowe, P., Elkin, S. L., Garrod, R., Greening, N. J., Heslop, K., Hull, J. H., Man, W. D.-C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203808 · Cited by 717
Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658
Adverse health effects of anabolic–androgenic steroids
van Amsterdam, J., Opperhuizen, A., & Hartgens, F. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.02.001 · Cited by 286
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review
Albano, G. D., Amico, F., Cocimano, G., Liberto, A., Maglietta, F., Esposito, M., Rosi, G. L., Di Nunno, N., Salerno, M., & Montana, A. (2021) · Healthcare · doi:10.3390/healthcare9010097 · Cited by 200
Christou, M. A., Christou, P. A., Markozannes, G., Tsatsoulis, A., Mastorakos, G., & Tigas, S. (2017) · Sports Medicine · doi:10.1007/s40279-017-0709-z · Cited by 199
Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids
Robles‐Diaz, M., Gonzalez‐Jimenez, A., Medina‐Caliz, I., Stephens, C., García‐Cortes, M., García‐Muñoz, B., Ortega‐Alonso, A., Blanco‐Reina, E., Gonzalez‐Grande, R., Jimenez‐Perez, M., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13023 · Cited by 98
National Athletic Trainers' Association Position Statement: Anabolic-Androgenic Steroids
Kersey, R. D., Elliot, D. L., Goldberg, L., Kanayama, G., Leone, J. E., Pavlovich, M., & Pope, H. G. (2012) · Journal of Athletic Training · doi:10.4085/1062-6050-47.5.08 · Cited by 73
Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review
Salerno, M., Cascio, O., Bertozzi, G., Sessa, F., Messina, A., Monda, V., Cipolloni, L., Biondi, A., Daniele, A., & Pomara, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24767 · Cited by 71
Tatem, A. J., Beilan, J., Kovac, J. R., & Lipshultz, L. I. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190002 · Cited by 66
McCullough, D., Webb, R., Enright, K. J., Lane, K. E., McVeigh, J., Stewart, C. E., & Davies, I. G. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09616-y · Cited by 62
“In addition to the genomic and non-genomic effects of AAS decreasing atrophy related gene expression and activity of catabolic pathways (FOXO pathway), AAS may cause direct inhibition on glucocorticoid receptor (GR) signalling and/or its expression [5].”
BackgroundBhasin, S., Krishnan, V., Storer, T. W., Steiner, M., & Dobs, A. S. (2023) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glad027 · Cited by 36
Novel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9649838 · Cited by 14
“Some of these are obtained by modification of the steroid structure, but others are nonsteroidal; it is an old concept, the myotrophic/androgenic index [41] as a major tool to evaluate androgen potency.”
Background
Metadata
- Authors
- Kicman, A. T.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-06
- Volume
- 154
- Issue
- 3
- Pages
- 502-521
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2146145065
- Cited by
- 580
- References
- 105
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.